Cara Therapeutics (DB:69C) - Hisse Senedi Fiyatı, Haberler ve Analizler

69C Stoklara Genel Bakış

69C temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	0/6

Ödüller

Gelirin yılda 46.37% oranında artması öngörülüyor

Risk Analizi

1 yıldan az nakit akışı var

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Anlamlı bir piyasa değeri yok ( €17M )

Cara Therapeutics, Inc. Rakipler

Biofrontera

XTRA:B8FK

€16.4m

SynBiotic

DUSE:SBX

€27.9m

Cantourage Group

XTRA:HIGH

€57.6m

Apontis Pharma

XTRA:APPH

€80.3m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Cara Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.27
52 Haftanın En Yüksek Seviyesi	US$1.13
52 Haftanın En Düşük Seviyesi	US$0.18
Beta	0.68
11 Aylık Değişim	28.68%
3 Aylık Değişim	-8.79%
1 Yıllık Değişim	-70.16%
33 Yıllık Değişim	-97.61%
5 Yıllık Değişim	-98.86%
Halka arzdan bu yana değişim	-97.39%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	69C	DE Pharmaceuticals	DE Pazar
7D	-14.3%	1.4%	0.8%
1Y	-70.2%	-18.4%	9.1%

Getiri vs. Endüstri: 69C geçen yıl % -18.4 oranında getiri sağlayan German Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: 69C geçen yıl % 9.1 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 69C's price volatile compared to industry and market?
69C volatility
69C Average Weekly Movement	17.0%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 69C hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 69C 'nin haftalık oynaklığı ( 17% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2004	55	Chris Posner	www.caratherapeutics.com

Geliştirme aşamasında bir biyofarmasötik şirketi olan Cara Therapeutics, Inc., Amerika Birleşik Devletleri'nde kronik kaşıntı tedavisine yönelik terapötikler geliştirmeye ve ticarileştirmeye odaklanmaktadır. Şirketin öncü ürünü, hemodiyalize giren yetişkinlerde kronik böbrek hastalığı (KBH) ile ilişkili orta ila şiddetli kaşıntının tedavisi için KORSUVA (difelikefalin) enjeksiyonudur. Ayrıca, notalgia paresthetica ile kronik kaşıntıyı tedavi etmek için Faz II/III klinik çalışmasında olan Oral difelikefalin geliştirmektedir.

Cara Therapeutics, Inc. Temel Bilgiler Özeti

Cara Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
69C temel i̇stati̇sti̇kler
Piyasa değeri	€15.95m
Kazançlar(TTM)	-€91.02m
Gelir(TTM)	€8.28m

1.9x

P/S Oranı

-0.2x

F/K Oranı

69C aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
69C gelir tablosu (TTM)
Gelir	US$8.69m
Gelir Maliyeti	US$111.11m
Brüt Kâr	-US$102.42m
Diğer Giderler	-US$6.90m
Kazançlar	-US$95.52m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.74
Brüt Marj	-1,179.18%
Net Kâr Marjı	-1,099.76%
Borç/Özkaynak Oranı	5,740.2%

69C uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

69C Stoklara Genel Bakış

Ödüller

Risk Analizi

Cara Therapeutics, Inc. Rakipler

XTRA:B8FK

€16.4m

DUSE:SBX

€27.9m

XTRA:HIGH

€57.6m

XTRA:APPH

€80.3m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Cara Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement under Nasdaq Listing Rule 5550(b)(1)

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$0.52 loss in 3Q 2023)

New major risk - Financial position

Second quarter 2024 earnings released: US$0.37 loss per share (vs US$0.58 loss in 2Q 2023)

Nasdaq Grants Cara Therapeutics Additional 180 Days to Regain Compliance with Minimum Closing Bid Price Requirement

Cara Therapeutics, Inc. Announces Outcome from Dose-Finding Part A of the Kourage-1 Study

Recent updates

Cara Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement under Nasdaq Listing Rule 5550(b)(1)

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$0.52 loss in 3Q 2023)

New major risk - Financial position

Second quarter 2024 earnings released: US$0.37 loss per share (vs US$0.58 loss in 2Q 2023)

Nasdaq Grants Cara Therapeutics Additional 180 Days to Regain Compliance with Minimum Closing Bid Price Requirement

Cara Therapeutics, Inc. Announces Outcome from Dose-Finding Part A of the Kourage-1 Study

First quarter 2024 earnings released: US$0.56 loss per share (vs US$0.49 loss in 1Q 2023)

Cara Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Cara Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

Full year 2023 earnings released: US$2.19 loss per share (vs US$1.59 loss in FY 2022)

Cara Therapeutics, Inc. to Report Q4, 2023 Results on Mar 04, 2024

Cara Therapeutics, Inc. Receives A Non-Compliance Notice from the Nasdaq Stock Market

Cara Therapeutics, Inc. Receives A Non-Compliance Notice from the Nasdaq Stock Market

Cara Therapeutics, Inc. Prioritizes Late-Stage Notalgia Paresthetica Program

Cara Therapeutics, Inc. Announces Outcome from Dose- Finding Part A of the KIND 1 Study Evaluating Oral Difelikefalin for Mod Moderate-To-Severe Pruritus in Patients with Atopic Dermatitis

New major risk - Financial position

Third quarter 2023 earnings released: US$0.52 loss per share (vs US$0.43 loss in 3Q 2022)

Cara Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.58 loss per share (vs US$0.078 loss in 2Q 2022)

Cara Therapeutics, Inc. Appoints Helen M. Boudreau as Member of Board and Audit Committee

Cara Therapeutics, Inc. Appoints Helen M. Boudreau to Board of Directors

Cara Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. Announces England’s National Institute for Health and Care Excellence has Recommended Kapruvia

First quarter 2023 earnings released: US$0.49 loss per share (vs US$0.52 loss in 1Q 2022)

Full year 2022 earnings released: US$1.59 loss per share (vs US$1.74 loss in FY 2021)

Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine

Third quarter 2022 earnings released: US$0.43 loss per share (vs US$0.02 loss in 3Q 2021)

Cara Therapeutics Announces Appointment of Lisa Von Moltke, M.D., to Its Board of Directors

Cara Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan

Key Executive recently sold €111k worth of stock

Cara Therapeutics, Inc Appoints Ryan Maynard as Principal Financial Officer and Principal Accounting Officer

Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress

Kapruvia® Gets Approval in Switzerland with Additional Regulatory Decisions

Second quarter 2022 earnings released: US$0.078 loss per share (vs US$0.61 loss in 2Q 2021)

Cara Therapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Cara Therapeutics, Inc. Announces Positive Topline Results from Komfort Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica

Cara Therapeutics, Inc. Announces Resignation of Thomas Reilly as Chief Financial Officer, Effective on or About June 15, 2022

First quarter 2022 earnings released: US$0.52 loss per share (vs US$0.47 loss in 1Q 2021)

Vifor Fresenius Medical Care Renal Pharma (Vfmcrp) and Cara Therapeutics, Inc. Announces the European Commission Has Granted Marketing Authorization to Kapruvia

Cara Therapeutics, Inc., Annual General Meeting, Jun 02, 2022

Cara Therapeutics, Inc Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. Announce CHMP Recommend Approval of Kapruvia for the Treatment of Moderate-To-Severe Pruritus in Hemodialysis Patients

Cara Therapeutics, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients

Independent Director recently sold €115k worth of stock

Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.35 loss in 3Q 2020)

Co-Founder recently sold €261k worth of stock

Cara Therapeutics and Vifor Pharma Announce U.S. FDA Approval of Korsuva™ (Difelikefalin) Injection for the Treatment of Moderate-To-Severe Pruritus in Hemodialysis Patients

Cara Therapeutics, Inc.(NasdaqGM:CARA) dropped from Russell Microcap Growth Index

First quarter 2021 earnings released: US$0.47 loss per share (vs US$0.62 loss in 1Q 2020)

Investor sentiment deteriorated over the past week

Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

Cara Therapeutics and Vifor Pharma Group Announce U.S. FDA Acceptance and Priority Review of NDA for KORSUVA™ Injection in Hemodialysis Patients with Moderate-To-Severe Pruritus

Full year 2020 earnings released: EPS US$0.18 (vs US$2.49 loss in FY 2019)

Revenue beats expectations

Cara Therapeutics, Inc. to Report Q4, 2020 Results on Feb 25, 2021